This site is intended for healthcare professionals

EU approves Keytruda for metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.- Merck Inc

Read time: 1 mins
Last updated:28th Jun 2021
Published:27th Jan 2021
Condition: Microsatellite Instability-High (MSI-H) cancer
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest